Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]

医药深度复盘+最新观点 春节期间，医药重要事件梳理 20260223 中国创新药对外授权 BD 交易活跃，截至 2 月 15 日，总首付款金额已达 30 亿美元，总体量 490 亿美元，远超 2025 年同期水平，预示 2026 年 BD 交易将大幅跃升。石药集团与阿斯利康合作金额高达 185 亿美元， 为近年来新高。 中国药企海外研发取得进展，如石药集团 PCSK9 小核酸新药 SYH2053 启动三期试验，科伦博泰卢康沙妥珠单抗启动全球临床试验，翰森制药 阿美替尼获欧盟批准，石药集团长效 GLP1/GIP 双抗 SYH2,082 获 FDA 批准 IND。 医改政策方面，《基要目录管理办法》修订强调与集采、医保衔接，原 则上每三年调整一次，集采纳入基要目录节奏或加快。已完成的集采政 策导向更温和，注重质量和反内卷，中选率达 93%，对市场结构影响较 小。 药品集采续约注重临床需求匹配度和投标供应商质量，覆盖率达 98%， 调整较小，趋向理性。续约采用询价方式，控制价格风险，符合反内卷 导向。前沿生物与 GSK 达成小核酸 BD 合作，首付款 4,000 万美元，里 程碑付款 9.63 亿美元，验证了早期研 ...

截至11:07，港股通创新药ETF(159570)标的指数热门股多数回调：石药集团、中国生物制药、三生制药、翰森制药、荣昌生物跌超5%，信达生物跌超4%， 康方生物跌超3%。 | 序号 | 代码 | 名称 | 估算板車 | 涨跌幅 | 17.47 80 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 1801 | 信达生物 | 10.51% | -0.56% | 6.81亿 | | 2 | 1093 | 石药集团 | 12.18% | -3.15% | 5.98 7. | | 3 | 6160 | 高密被田 | 10.99% | -1.13% | 2.83 Z | | 4 | 1530 | 三生制药 | 6.50% | -2.57% | 2.65 Z | | 5 | 9926 | 康方生物 | 8.49% | -1.33% | 2.57 Z | | 6 | 3692 | 翰森制药 | 6.84% | -1.84% | 1.99 Z | | 7 | 1177 | 中国生物制药 | 10.01% | -3.66% | 1.74Z | | 8 | 6990 | 科伦博 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]